These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31471310)

  • 21. Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
    Rice SJ; Liu X; Hyland V; Liu Z; Belani CP
    Lung Cancer; 2020 Mar; 141():97-100. PubMed ID: 31986371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrating NGS-derived mutational profiling in the diagnosis of multiple lung adenocarcinomas.
    Ezer N; Wang H; Corredor AG; Fiset PO; Baig A; van Kempen LC; Chong G; Issac MSM; Fraser R; Spatz A; Riviere JB; Broët P; Spicer J; Camilleri-Broët S
    Cancer Treat Res Commun; 2021; 29():100484. PubMed ID: 34773797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological and Molecular Study of Peritoneal Carcinomatosis Associated with Non-Small Cell Lung Carcinoma.
    Nassereddine H; Sannier A; Brosseau S; Rodier JM; Khalil A; Msika S; Danel C; Couvelard A; Théou-Anton N; Cazes A
    Pathol Oncol Res; 2020 Oct; 26(4):2795-2800. PubMed ID: 31407221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does histological assessment accurately distinguish separate primary lung adenocarcinomas from intrapulmonary metastases? A study of paired resected lung nodules in 32 patients using a routine next-generation sequencing panel for driver mutations.
    Bruehl FK; Doxtader EE; Cheng YW; Farkas DH; Farver C; Mukhopadhyay S
    J Clin Pathol; 2022 Jun; 75(6):390-396. PubMed ID: 33649140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multidisciplinary approach for the differential diagnosis between multiple primary lung adenocarcinomas and intrapulmonary metastases.
    Belardinilli F; Pernazza A; Mahdavian Y; Cerbelli B; Bassi M; Gradilone A; Coppa A; Pignataro MG; Anile M; Venuta F; Della Rocca C; Giannini G; d'Amati G
    Pathol Res Pract; 2021 Apr; 220():153387. PubMed ID: 33647865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Next-Generation Sequencing: A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases.
    Patel SB; Kadi W; Walts AE; Marchevsky AM; Pao A; Aguiluz A; Mudalige T; Liu Z; Deng N; Lopategui J
    J Mol Diagn; 2017 Nov; 19(6):870-880. PubMed ID: 28866070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.
    Tang R; Zhong T; Dang Y; Zhang X; Li P; Chen G
    Clin Transl Oncol; 2016 Apr; 18(4):360-8. PubMed ID: 26307752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-risk human papillomavirus-positive lung cancer: molecular evidence for a pattern of pulmonary metastasis.
    van Boerdonk RA; Daniels JM; Bloemena E; Krijgsman O; Steenbergen RD; Brakenhoff RH; Grünberg K; Ylstra B; Meijer CJ; Smit EF; Snijders PJ; Heideman DA
    J Thorac Oncol; 2013 Jun; 8(6):711-8. PubMed ID: 23571474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies.
    Shen E; Xiu J; Bentley R; López GY; Walsh KM
    Clin Lung Cancer; 2020 Nov; 21(6):e523-e527. PubMed ID: 32414627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
    Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR
    Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted RNA sequencing with touch imprint cytology samples for non-small cell lung cancer patients.
    Seto K; Masago K; Fujita S; Haneda M; Horio Y; Hida T; Kuroda H; Hosoda W; Okubo KI
    Thorac Cancer; 2020 Jul; 11(7):1827-1834. PubMed ID: 32372482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.
    Lebanony D; Benjamin H; Gilad S; Ezagouri M; Dov A; Ashkenazi K; Gefen N; Izraeli S; Rechavi G; Pass H; Nonaka D; Li J; Spector Y; Rosenfeld N; Chajut A; Cohen D; Aharonov R; Mansukhani M
    J Clin Oncol; 2009 Apr; 27(12):2030-7. PubMed ID: 19273703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
    Lee K; Kim D; Yoon S; Lee DH; Kim SW
    Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.
    Xi Y; Bai Z; Gao S; Guo J; Zhang Z; Zhang H; Qu L; Xu B; Wang W; Shan G; Cui W; Bai W; Ji X
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8573-8580. PubMed ID: 37186065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
    Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
    Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of real-life data from patients with NGS panel negative and
    Gökyer A; Küçükarda A; Köstek O; Gökmen İ; Özcan E; Sayın S; Taştekin E; Hacıoğlu B; Erdoğan B; Uzunoğlu S; Çiçin İ
    Tumori; 2022 Apr; 108(2):141-146. PubMed ID: 33624577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.